Review finds limited but positive evidence for grapiprant in dogs

Version 1

A new evidence review in Veterinary Evidence suggests grapiprant can help some dogs with chronic osteoarthritis, but the case for it is still limited. The April 14, 2026 review by Grace Olding and Merran Govendir evaluated two randomized controlled trials and rated the overall strength of evidence as weak. One trial found significant improvement in owner-reported pain and function, as well as veterinarian-assessed orthopedic scores, versus placebo in dogs with naturally occurring osteoarthritis. The second, an acute induced-arthritis study, found no significant benefit for grapiprant on lameness measures, underscoring a gap between chronic clinical use and acute experimental pain models. Grapiprant is marketed as Galliprant, an EP4 receptor antagonist approved by the FDA in March 2016 for control of pain and inflammation associated with canine osteoarthritis. (veterinaryevidence.org)

Why it matters: For veterinary professionals, the review is a reminder that grapiprant has some supportive clinical-trial data, but not a deep evidence base. The pivotal field study behind FDA approval showed a higher treatment-success rate than placebo after 28 days, while labeling and published safety data point to gastrointestinal signs such as diarrhea, vomiting, and inappetence as the most common adverse reactions. A broader narrative review published previously also concluded grapiprant appears better suited to chronic than acute pain, which aligns with the mixed results highlighted in the new evidence summary. (dailymed.nlm.nih.gov)

What to watch: More head-to-head and longer-term studies will be needed to clarify where grapiprant fits relative to other canine OA options, especially in chronic multimodal pain plans. (veterinaryevidence.org)